Advertisement

Topics

Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1.

08:00 EDT 11th October 2018 | BioPortfolio

Summary of "Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1."

Abnormal regulation of cholesterol homeostasis is associated with type 2 diabetes mellitus (T2DM) and multiple other diseases. Glucagon-like peptide-1 (GLP-1) has unique effects on modulating hepatic lipid metabolism. However, the mechanism behind these is largely unknown. The aim of this study was to investigate the effects of GLP-1 on cholesterol-induced lipotoxicity in hepatocytes and examine the underlying mechanisms.

Affiliation

Journal Details

This article was published in the following journal.

Name: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
ISSN: 1421-9778
Pages: 679-693

Links

DeepDyve research library

PubMed Articles [14839 Associated PubMed Articles listed on BioPortfolio]

Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice.

Mucositis is a side effect of chemotherapy seen in the digestive tract, with symptoms including pain, diarrhoea, inflammation and ulcerations. Our aim was to investigate whether endogenous glucagon-li...

Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1.

The glucagon-like peptide 1 receptor (GLP-1R) can be activated by a number of endogenous peptide hormones, including extended, processed, glycine extended and carboxy-terminally amidated versions of g...

Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice.

Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for its beneficial vasoactive effects. However, ADM is also known to inhibit insulin secretion, ...

Bacterial metabolite S-equol modulates glucagon-like peptide-1 secretion from enteroendocrine L cell line GLUTag cells via actin polymerization.

S-equol is one of gut bacterial metabolites produced from soybean isoflavone daizein. While S-equol is known to promote glucose-induced insulin secretion from pancreatic β cells, whether S-equol affe...

Lack of Pancreatic Safety Concern Following Glucagon-Like Peptide-1 Receptor Agonist Therapies: A Pooled Analysis of Four Cardiovascular Outcome Trials.

Evidence on the pancreatic safety of glucagon-like peptide-1 receptor agonist therapy has been limited. The objective of the study was to investigate this issue by pooling data on the incidence of acu...

Clinical Trials [4772 Associated Clinical Trials listed on BioPortfolio]

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin releas...

Glucagon Modulation of Ghrelin Secretion

As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulate...

Glucagon Like Peptide-1 in Remote Ischemic Conditioning

The study was designed to investigate whether glucagon like peptide-1 is a mediator of protection of endothelial function induced by remote ischemic conditioning in ischemia-reperfusion

Effect of Bariatric Surgery on Bile Acid Homeostasis

The purpose of this study is to evaluate the effect of bariatric surgery in bile acid homeostasis and its interrelationship with the metabolic changes induced by the surgery. This study c...

The Effects of Neprilysin on Glucagon-like Peptide-1

In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor

Medical and Biotech [MESH] Definitions

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

A receptor for GLUCAGON-LIKE PEPTIDE 2 (GLP-2) that is expressed on the surface of intestinal cells as well as neural cells. GLP-2 and other peptides act through GLP-2R to regulate cellular responses to BLOOD GLUCOSE, INFLAMMATION, and FOOD INTAKE.

A steroid hydroxylase that functions in CHOLESTEROL homeostasis in the brain. It converts cholesterol into 24S-hydroxycholesterol, which is transported over the BLOOD-BRAIN BARRIER more rapidly than unmetabolized cholesterol.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topic

Lipitor
Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is prescribed to lower cholesterol and triglycerides in the the...


Searches Linking to this Article